A new Centers for Medicare & Medicaid Services (CMS) study on medication therapy management brings "further proof" of the benefits of pharmacist-led MTM services in improving patient health and mitigating medical costs, according to Steve Anderson, president and chief executive officer of the National Association of Chain Drug Stores.


National Association of Chain Drug Stores, NACDS, Steve Anderson, Centers for Medicare & Medicaid Services, CMS, medication therapy management, pharmacist, community pharmacies




























































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Retail News Breaks Archives

NACDS touts findings of CMS study on MTM

February 7th, 2013

ARLINGTON, Va. – A new Centers for Medicare & Medicaid Services (CMS) study on medication therapy management brings "further proof" of the benefits of pharmacist-led MTM services in improving patient health and mitigating medical costs, according to Steve Anderson, president and chief executive officer of the National Association of Chain Drug Stores.

NACDS said Thursday that the CMS study released this week, "Medication Therapy Management (MTM) in a Chronically Ill Population: Interim Report," describes reduced prescription drug and hospitalization costs among patients with congestive heart failure (CHF) and chronic obstructive pulmonary disease (COPD) who were newly enrolled in a Medicare Part D MTM program in 2010.

"This CMS study shows yet again that public and private payers who pursue pharmacist-provided MTM are on the right track for improving the effectiveness, quality and affordability of patient care," Anderson said in a statement. "This is exactly why NACDS has focused on the priority of further advancing MTM through legislation and raising awareness of its value within the private sector. When it comes to patient care and smarter approaches to health care, MTM is a winner."

The CMS study found that in comparison to Medicare beneficiaries with CHF or COPD who didn't receive any MTM services in 2010, those enrolled in MTM programs — and especially those who received annual comprehensive medication reviews (CMRs) — "experienced significant improvements in the quality of their drug regimens."

NACDS noted that in the 112th Congress, the association supported legislation to improve Medicare's MTM benefit, and efforts are under way to foster support for such a legislative initiative in the 113th Congress.

"Community pharmacies are widely recognized for their core function of helping patients use medicines safely and stay healthy," Anderson added. "Innovative pharmacy services, including MTM, do even more to improve health, quality of life and health care affordability. This is particularly true for many Americans in the greatest need."

Advertisement